Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 September 2019 | Story Ruan Bruwer
Louzanne  and her guide, Estean Badenhorst.
Louzanne Coetzee ran a new national record time in the 1 500 m in Paris. Pictured with her is her guide, Estean Badenhorst.

The blind UFS athlete Louzanne Coetzee has broken yet another national record.

The South African 1 500 m record in the T11 classification (totally blind) will have the same name next to it, but a new time – as the previous record also belonged to Coetzee.

She clocked a personal best time of 4:51:65 at the Paris Para Athletics Grand Prix meeting over the weekend. The previous record was set at the World Para Championships in London in July 2017. Coetzee is also the world record holder in the 5 000 m and the African record holder in the 800 m.

Her time in Paris is good enough to take her to a second Paralympic Games. The qualification standards for the games in Tokyo is 06:20.00.

Estean Badenhorst – as her guide – accompanied her. “I have run with him before but couldn’t make use of his services last year due to his study commitments. It is a great privilege to run with him. Estean is a fantastic strategic guide. I hope we can join forces again in the future,” Coetzee said. 

Emphasis now on 1 500 m 

The 800 m and 5 000 m are not on the Paralympic programme; this shifted her focus to the 1 500 m, in which she will participate at the World Para Athletics Championships in Dubai in early November.

“This is now my main focus in the run-up to the Paralympics next year,” says Louzanne. 

She has already qualified for the Paralympics in the marathon, but this will play second fiddle to the track, said the 26-year-old, who is doing her master’s in Social Cohesion and Reconciliation Studies this year.

According to Rufus Botha, a respected athletic coach who previously coached Coetzee, her time in Paris was excellent. “This predicts a great World Champs where Louzanne seems ready for her first medal at a World Championship,” he said.

News Archive

Heart-valve studies receive international recognition
2017-07-11

 Description: Heart-valve studies  Tags: Heart-valve studies  

Prof Francis Smit, Head of the Department of
Cardiothoracic Surgery at the UFS, and Manager of the
Robert WM Frater Cardiovascular Research Centre, with
Kyle Davis, Mechanical Engineer at the centre.

Photo: Rulanzen Martin

Three heart-valve studies which have been developed at the Robert WM Frater Cardiovascular Research Centre at the School of Medicine at the University of the Free State (UFS) were recently presented in Monte Carlo at the conference of the prestigious global Heart Valve Society (HVS).

These studies are all headed by Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS, and Manager of the Robert WM Frater Cardiovascular Research Centre.
Prof Smit says the HVS is a combination of the former heart-valve societies of Europe and the US. “Studies on heart-valve disease, heart-valve-related products and operations, as well as the design and development of new valves were presented. There are both clinical and development divisions.

He says the study in which the hemodynamics of their redesigned mechanical poppet valve was compared to a commercial bi-leaflet mechanical heart valve, was named as the best poster presentation in the experimental valve development and numerical flow dynamics division. The study, which was presented by Kyle Davis, mechanical engineer at the centre, competed against some of the best heart-valve research units in the world.

The redesigned valve, based on the 1960s Cape Town poppet valve, has the potential to provide a low-cost solution for mechanical heart-valve replacement. It is possible to produce the titanium ring with 3-D printers and is, together with the silicon poppet valve, extremely inexpensive compared to current mechanical valve-manufacturing processes.
The advantages of this valve over current mechanical valves is that, due to the effective and laminar flow characteristics, as well as the simple locking mechanisms, there is a reduced chance of valve thrombosis, and the need for anti-clotting drugs is therefore limited.

It was also confirmed that the new valve more than meets the published FDA (Federal Drug Agency) requirements, which determine the minimum standards of valves for human use in the US.

The redesigned valve also has a very low platelet activation impact, which is responsible for platelet thrombosis and leads to valve thrombosis or strokes. This valve is another heart-valve project by the centre, which is also in the process of evaluating a tri-leaflet polyurethane valve developed by them.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept